PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg.

Slides:

Advertisements

Similar presentations

Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,

Advertisements

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need

Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)

Patients with Rheumatoid Arthritis in Comparison to Other Connective Tissue Diseases Are Mostly Influenced by Concomitant Fibromyalgia Tomš J, Daňková.

Table 1. Comparison between the provisional diagnosis based on the proforma versus final diagnosis Early arthritis Rheumatoid arthritis 3 6 Psoriatic.

The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,

What is the definition of remission in RA? American Rheumatism Association (ARA)¹ Five or more of the following criteria must be fulfilled for at least.

Measuring Signs and Symptoms in Rheumatoid Arthritis David R. Karp, MD, PhD Chief, Rheumatic Diseases UT Southwestern Medical Center David R. Karp, MD,

Rituximab for the Treatment of Rheumatoid Arthritis

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.

Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.

Yusuf Yazıcı, MD NYU Hospital for Joint Diseases

Achieving remission in early RA Dubai, United Arab Emirates 19. January 2009 Professor Joachim Kalden Friedrich-Alexander University Erlangen-Nuremberg.

An assessment tool for dactylitis Philip Helliwell.

Non-Radiographic Spondyloarthritis Has Greater Work Instability than Other Spondyloarthritis Subtypes in a National Database Sherry Rohekar 1, Robert D.

Rehabilitation Teaching and Research Unit, Wellington School of Medicine and Health Sciences Outcome measures in psoriatic arthritis Preliminary identification.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Philip Helliwell, Arthur Kavanaugh, Gerry Krueger, Peter.

1 Assessing the Minimally Important Difference in Health-Related Quality of Life Scores Ron D. Hays, Ph.D. UCLA Department of Medicine October 25, 2006,

Yusuf Yazıcı, MD NYU Hospital for Joint Diseases, New York

EFFICACY OF SPA THERAPY IN RHEUMATOID ARTHRITIS-A RANDOMISED CONTROLLED CLINICAL STUDY Mine Karagülle Department of Medical Ecology and Hydroclimatology.

TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.

Saving time and improving care with a multidimensional health assessment questionnaire: 10 practical considerations T Pincus, Y Yazici, M Bergman J Rheumatol.

OMERACT 8 PsA Module Co-Chairs Dafna Gladman and Philip Mease Steering Committee Alice Gottlieb, Oliver FitzGerald, Philip Helliwell, Arthur Kavanaugh,

Axial Spondyloarthritis (SpA): Representative Values of Sensitivity and Specificity for Several Tests with the Resulting LRs *LR+ = sensitivity/(1 – specificity);

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

Outcome measures for balneotherapy NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY Budapest, Hungary Dr. LÁSZLÓ HODINKA Recommendations.

1 Session 6 Minimally Important Differences Dave Cella Dennis Revicki Jeff Sloan David Feeny Ron Hays.

GRAPPA Meeting, Oct. 16, 2004 San Antonio, Texas Patient Global Question Alberto Cauli Rheumatology Division University of Cagliari, Italy Director Prof.

EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with RA, Non-Inflammatory Disorders (NIRD), and Fibromyalgia (FM)

OMERACT Workshop Outcome Measures in Psoriatic Arthritis

Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.

Outcome Measures in PsA Philip Mease MD Seattle, WA.

GRAPPA Guidelines for PsA: Considerations GRAPPA Guidelines Mission Statement: “To develop guidelines, based upon the best scientific evidence, for the.

GRAPPA Committee Reports and Outcome measures Dafna D. Gladman, MD, FRCPC Professor of Medicine, University of Toronto Director, PsA Program, University.

Psoriatic Arthritis Workshop OMERACT 7 Steering Committee Dafna Gladman, Philip Mease, Gerald Krueger, Désirée van der Heijde, Christian Antoni, Philip.

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.

Disease Activity Scales in Patients with UPIA

Anti-TNF therapy improves hand function in rheumatoid arthritis

Patient Baseline Assessment

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Rheumatoid Arthiritis

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Clinical response in patients with early and established RA at month 24. *p

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

Effect sizes (95% CI) of clinical variables per treatment group of studies directly comparing different dosages/routes. Effect sizes (95% CI) of clinical.

Multivariable model of adjusted

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Presentation transcript:

PsA: Review of Available Assessment Instruments and Lessons from Trial Results Part II Christian Antoni Friedrich Alexander University Erlangen-Nürnberg Department of Medicine III

Antoni N.Y. 8/03 Outline Baseline characteristics of actual trial patients Joint count vs. joint score Used and not used assessment instruments MRI and Ultrasound

Antoni N.Y. 8/03 The IMPACT Trial Centers Kalden/AntoniErlangen, Germany Burmester/SchneiderBerlin, Germany Smolen/EbnerVienna, Austria Kirkham London, United Kingdom Keystone/GladmanToronto, Canada Kavanaugh/TutuncuSan Diego, California Weisman/WallaceLos Angeles, California Furst/MolitorSeattle, Washington WassenbergRatingen, Germany

Antoni N.Y. 8/03 IMPACT Inclusion Criteria > 18 years old PsA with peripheral polyarticular involvement for >6 months Typical psoriatic arthritis presentation with /without active skin lesions –Arthritis der DIP-Gelenke an Händen und Füßen –Arthritis mutilans mit Sakroilitis –Symmetrische Arthritis, klinisch wie die RA imponierend aber ohne RF –Asymmetrische Oligoarthritis mit Beteiligung der kleinen Gelenke (Wurstfinger) –Ankylosierende Spondylitis mit oder ohne periphere Arthritis (Moll and Wright 1973) Negative for RF

Antoni N.Y. 8/03 IMPACT Inclusion Criteria Active disease (5 joints and ESR>28, or CRP> 15, or morning stiffness > 45 minutes) At least 1 DMARD failure Stable DMARD dosing > 4 weeks, if applicable Stable prednisone <10 mg/day for 2 weeks Stable NSAIDS for 2 weeks

Antoni N.Y. 8/03 Patient Population Psoriasis duration (mean)18.8 years –Mean age at diagnosis26.7 years Arthritis duration (mean)11.0 years –Mean age at diagnosis 34.4 years Concomitant DMARDs treatment (69/101 patients) –Leflunomide6 –Sulfasalazine8 –Methotrexate56 –Mean DMARD 1.85 all patients 2.09 Infliximab 1.86 Placebo

Antoni N.Y. 8/03 Mean Baseline Activity PlaceboInfliximab Tender-joint count2024 Swollen-joint count1415 Physician global (0-100)5354 Patient global (0-100) 5752 Patient pain (0-100)5754 HAQ disability index (0-3) CRP (mg/L)2123

Antoni N.Y. 8/03 Baseline PASI PlaceboInfliximab n = 52n = 52 Subjects with Any Skin n= 42n= 42 Involvement Subjects with PASI >2.5n = 18n = 21 Mean Baseline 7.96 ( ) 8.88 ( )

Antoni N.Y. 8/03 Week 16 Results: PASI PlaceboInfliximab Mean PASI Baseline Mean PASI Week % Change of Mean-29.6%81.5%* > 75% Improvement1 subjects 14 subjects (0.05%) (67%)** *p<0.001 **p<0.0001

Antoni N.Y. 8/03 Week 50 Results: PASI Placebo + InfliximabInfliximab Mean PASI Baseline Mean PASI Week % Change of Mean47.6%72.1%* > 75% Improvement8 subjects 12 subjects (44%) (57%)** *p<0.001 **p<0.0001

Antoni N.Y. 8/03 Outline Baseline characteristics of actual trial patients Joint count vs. joint score Used and not used assessment instruments MRI and Ultrasound

Antoni N.Y. 8/03

Intra and Inter Observer Variability Intra-rater variability shows good correlation Hernandez-Cruz B, Clin Exp Rheum 199 “inter-rater agreement hardly exceeds the chance level when degree of tenderness is independently assessed” Hart 1985, Lewis 1988, Thompson 1991, Scott 1992

Antoni N.Y. 8/03 Count vs. Score Tenderness

Antoni N.Y. 8/03 Count vs. Score Swelling

Antoni N.Y. 8/03 Week 16 Results: ACR 20, 50, 70 counts vs. score Percent of Patients Responding *p<0.0001

Antoni N.Y. 8/03 Outline Baseline characteristics of actual trial patients Joint count vs. joint score Used and not used assessment instruments: –Clegg Criteria –ACR –DAS and DAS28 –HAQ and SF36 –RADAI MRI and Ultrasound

Antoni N.Y. 8/03 Combined Indices Paulus Criteria (Arthritis. Rheum. 1990) ACR Preliminary Definition of Improvement in Rheumatoid Arthritis (Arthritis. Rheum. 1995) EULAR Criteria, "Disease Activity Index" DAS (J Rheumatol 1993) PsARC or Clegg Criteria (Arhtritis Rheum 1996)

Antoni N.Y. 8/03 Clegg or PsARC Criteria Improvement is defined as: Improvement in 1 out of 4 criterias including one out of JTS or JSS –30% improvement in TJS –30% improvement in JSS –Patient Global on a Liquert scale (1 out of 4) –Doctors global on a Liquert scale (1 out of 4) For improved cases non of the 4 criteria is allowed to worse by the defined changes

Antoni N.Y. 8/03 ACR20 Criteria of Improvement  20% improvement in swollen and tender joints and  20% improvement in 3 of the 5 assessments: –patient’s assessment of pain (VAS) –patient’s globa assessment of disease activity (VAS) –evaluator’s global assessment of disease activity (VAS) –patient’s assessment of physical function (HAQ) –CRP or ESR

Antoni N.Y. 8/03 Disease Activity Score (DAS) Composite Index incorporating: –ESR –Swollen joint count –Ritchie Index of articular tenderness (score) –Assessment of patient’s general health DAS28 (28 joint count) as reliable as DAS (53/44 joint count)

Antoni N.Y. 8/03 DAS 28 Tender joint count (28) Swollen joint count (28) ESR Patient Global (0-100 mm) DAS = 0,555 (28 TJC.)+ 0,284 (28 SJC.) + 0,70 In (ESR) + 0,0142 (patient global)

Lindenbaum-On-screen 23 EULAR Response Criteria DAS28 at Endpoint Improvement in DAS or DAS28 from Baseline  3.2 > 3.2 and  5.1 > 5.1 > 1.2 > 0.6 and  1.2  0.6 Good Moderate None

Antoni N.Y. 8/03 Rheumatoid Arthritis: Patient 3 infliximab

Antoni N.Y. 8/03 20% ACR20 vs DAS28: same improvement, different level of disease activity

Antoni N.Y. 8/ ACR AUC 6.1 ACR AUC Same level of disease activity, different baseline value AUC ACR influence of baseline

Antoni N.Y. 8/03 Week 16 Results PsARC *p< Percent of Patients

Antoni N.Y. 8/03 Week 16 Results: ACR 20, 50, 70 Percent of Patients Responding *p<0.0001

Antoni N.Y. 8/03 Week 16 Results Proportion of DAS 28 Responders Patients with a Good or Moderate DAS28 Response at Week 16 Percent of Patients

Antoni N.Y. 8/03 Week 16 Results Proportion of DAS Original Responders Patients with a Good or Moderate DAS Response at Week 16 Percent of Patients

Antoni N.Y. 8/03 20 questions in eight categories of function: The Health Assessment Questionnaire (HAQ) Functional Disability Index (FDI) n dressing n arising n eating n walking n hygiene n reach n grip n activities aids, devices or help by another person

Antoni N.Y. 8/03 Reduction of Efficacy parameters at week 16 ACR individual parameters Parameterbaselineweek 16change % Placebo/Infliximab Tender joint score:25/3127/14-30/62 Swollen joint score:17/1716/54/68 Patient Global VAS:56/5258/25-10/49 Patient VAS of pain:57/5458/22-3/55 Physician Global VAS:53/5553/20-5/61 HAQ:1.19/ /0.68/47 CRP:12/1211/2-23/62

Antoni N.Y. 8/03 Medical Outcomes Study Short-Form-36 (SF-36) Generic health status measure containing 36 items on 8 different aspects of health 1 – physical functioning 2 – physical role 3 – mental health 4 – emotional health 5 – bodily pain 6 – social functioning 7 – generic health 8 – vitality

Antoni N.Y. 8/03 SF-36 Most widely used generic measure of health status Numerous methods of scoring and analysing the data Can be used in comparisons –between patients and the general population, –between severity groups and over time scores can be linked to a range of interpretations, including distribution and norm or anchor based

Antoni N.Y. 8/03 SF-36 RA Comparison European cohorts

Antoni N.Y. 8/03 Patient vs. physician assessment of the patient’s health today RA? Best imaginable Worst imaginable Mean=3.8 +/- 2.1Mean=5.0 +/- 2.4

Antoni N.Y. 8/03 RADAI n Self Description  The RADAI is a useful method as a complement to physician’s assessments in long-term observation studies n Rationale for use  The questionnaire is short, easy to use, valid, reliable, and sensitive to change in disease activity EULAR Handbook of Clinical Assessment P-47

Antoni N.Y. 8/03 Fransen et al (observational study in 584 patients with rheumatoid arthritis) n good test-retest-correlation ( ) n weak correlation with the ESR (0.27) n correlation with tender joint count 0.55 n correlation with physician´s global assessment 0.59 n correlation with DAS28: 0.56 Rheumatoid Arthritis Disease Activity Index (RADAI)

Antoni N.Y. 8/03 Mean RADAI RA by Country N=5173, mean = 4.11

Antoni N.Y. 8/03 RADAI vs. Tender joints in RA N=5084

Antoni N.Y. 8/03 RADAI vs HAQ in RA

Antoni N.Y. 8/03 Outline Baseline characteristics of actual trial patients Joint count vs. joint score Used and not used assessment instruments MRI and Ultrasound

Antoni N.Y. 8/03

correlation MRI with joint counts Correlation with % change of Gadolinium uptake Tender Joint Scorer = 0,62p = 0,04 Swollen Joint scorer = 0,772p = 0,008 Physician evaluation of disease activity r = 0,82p = 0,006 Patient evaluation of disease activity r = 0,74p = 0,009 Morning stiffnessr = 0,639p = 0,027

Antoni N.Y. 8/03 Infliximab Reduces Inflammation in Psoriatic Arthritis MRI Scan of wrist – Gadolinium Uptake Week 0 Week 10 Antoni C et al. EULAR 2000.